Zimmer Biomet (ZBH) Stock Forecast, Price Target & Predictions
ZBH Stock Forecast
Zimmer Biomet stock forecast is as follows: an average price target of $137.17 (represents a 29.09% upside from ZBH’s last price of $106.26) and a rating consensus of 'Hold', based on 19 wall street analysts offering a 1-year stock forecast.
ZBH Price Target
The average price target for Zimmer Biomet (ZBH) is $137.17 based on 1-year price targets from 19 Wall Street analysts in the past 3 months, with a price target range of $180.00 to $112.00. This represents a potential 29.09% upside from ZBH's last price of $106.26.
ZBH Analyst Ratings
According to 19 Wall Street analysts, Zimmer Biomet's rating consensus is 'Hold'. The analyst rating breakdown for ZBH stock is 0 'Strong Buy' (0.00%), 8 'Buy' (42.11%), 10 'Hold' (52.63%), 1 'Sell' (5.26%), and 0 'Strong Sell' (0.00%).
Zimmer Biomet Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Richard Newitter | Truist Financial | $112.00 | $105.14 | 6.52% | 5.40% |
| Sep 10, 2024 | Caitlin Cronin | Canaccord Genuity | $115.00 | $104.83 | 9.70% | 8.23% |
| Aug 08, 2024 | Jayson Bedford | Raymond James | $128.00 | $107.09 | 19.53% | 20.46% |
| Aug 08, 2024 | Steven Lichtman | Oppenheimer | $145.00 | $105.81 | 37.04% | 36.46% |
| Aug 07, 2024 | Rick Wise | Stifel Nicolaus | $130.00 | $107.50 | 20.94% | 22.34% |
| Jul 15, 2024 | Drew Ranieri | Morgan Stanley | $120.00 | $108.69 | 10.41% | 12.93% |
| Jul 01, 2024 | Matt O'Brien | Piper Sandler | $115.00 | $108.53 | 5.96% | 8.23% |
| May 31, 2024 | Matthew O\'Brien | Piper Sandler | $140.00 | $114.44 | 22.33% | 31.75% |
| May 30, 2024 | Shagun Singh | RBC Capital | $140.00 | $115.14 | 21.59% | 31.75% |
| May 28, 2024 | Ryan Zimmerman | BTIG | $139.00 | $116.41 | 19.41% | 30.81% |
The latest Zimmer Biomet stock forecast, released on Sep 13, 2024 by Richard Newitter from Truist Financial, set a price target of $112.00, which represents a 6.52% increase from the stock price at the time of the forecast ($105.14), and a 5.40% increase from ZBH last price ($106.26).
Zimmer Biomet Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 7 | 11 |
| Avg Price Target | $113.50 | $123.57 | $130.36 |
| Last Closing Price | $106.26 | $106.26 | $106.26 |
| Upside/Downside | 6.81% | 16.29% | 22.68% |
In the current month, the average price target of Zimmer Biomet stock is $113.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 6.81% increase as opposed to Zimmer Biomet's last price of $106.26. This month's average price target is down -8.15% compared to last quarter, and down -12.93% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Sep 13, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 13, 2024 | Barclays | - | Underweight | Downgrade |
| Sep 13, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Sep 10, 2024 | Canaccord Genuity | Hold | Hold | Hold |
| Sep 09, 2024 | Wolfe Research | - | Peer Perform | Initialise |
| Sep 05, 2024 | UBS | Equal-Weight | Equal-Weight | Hold |
| Sep 05, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Sep 05, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Sep 05, 2024 | Citigroup | Neutral | Neutral | Hold |
Zimmer Biomet's last stock rating was published by Goldman Sachs on Sep 13, 2024. The company gave ZBH a "Buy" rating, the same as its previous rate.
Zimmer Biomet Financial Forecast
Zimmer Biomet Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $183.70M | $1.75B | $1.87B | $1.83B | $1.83B | $1.67B | - | $1.66B | $2.04B | $1.92B | $2.03B | $1.85B | $2.09B | $1.93B |
| Avg Forecast | $2.38B | $2.11B | $2.23B | $2.17B | $2.25B | $2.00B | $2.13B | $2.06B | $2.16B | $1.92B | $2.04B | $1.98B | $2.05B | $1.82B | $1.94B | $1.87B | $1.93B | $1.75B | $1.83B | $1.70B | $1.76B | $1.63B | $1.72B | $1.59B | $2.07B | $1.94B | $1.97B | $1.76B | $2.08B | $1.71B |
| High Forecast | $2.43B | $2.16B | $2.27B | $2.21B | $2.30B | $2.05B | $2.17B | $2.10B | $2.20B | $1.96B | $2.08B | $2.02B | $2.09B | $1.84B | $1.98B | $1.91B | $1.97B | $1.77B | $1.86B | $1.74B | $1.80B | $1.67B | $1.72B | $1.61B | $2.10B | $1.97B | $2.00B | $1.79B | $2.11B | $1.74B |
| Low Forecast | $2.32B | $2.07B | $2.18B | $2.12B | $2.20B | $1.96B | $2.08B | $2.01B | $2.11B | $1.88B | $1.99B | $1.93B | $2.00B | $1.78B | $1.90B | $1.83B | $1.88B | $1.73B | $1.79B | $1.67B | $1.72B | $1.60B | $1.72B | $1.57B | $2.04B | $1.92B | $1.95B | $1.74B | $2.06B | $1.69B |
| # Analysts | 8 | 10 | 16 | 8 | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 10 | 18 | 21 | 10 | 10 | 13 | 9 | 9 | 17 | 11 | 10 | 20 | 10 | 14 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.10% | 1.00% | 1.02% | 1.07% | 1.04% | 1.02% | - | 1.05% | 0.99% | 0.99% | 1.03% | 1.05% | 1.00% | 1.13% |
Zimmer Biomet's average Quarter revenue forecast for Mar 24 based on 10 analysts is $1.87B, with a low forecast of $1.83B, and a high forecast of $1.91B. ZBH's average Quarter revenue forecast represents a 916.57% increase compared to the company's last Quarter revenue of $183.70M (Dec 23).
Zimmer Biomet EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 10 | 16 | 8 | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 10 | 18 | 21 | 10 | 10 | 13 | 9 | 9 | 17 | 11 | 10 | 20 | 10 | 14 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $183.70M | $266.60M | $329.60M | $609.90M | $454.40M | $491.40M | - | $422.20M | $420.20M | $531.10M | $556.40M | $576.80M | $549.90M | $593.70M |
| Avg Forecast | $676.89M | $602.05M | $634.60M | $617.22M | $641.38M | $570.95M | $605.43M | $586.98M | $613.85M | $547.47M | $580.14M | $563.67M | $583.26M | $517.55M | $552.51M | $435.46M | $549.21M | $498.06M | $520.19M | $344.23M | $501.52M | $510.00M | $490.39M | $272.12M | $178.00M | $463.64M | $478.38M | $478.24M | $501.52M | $389.67M |
| High Forecast | $691.02M | $614.60M | $647.84M | $630.10M | $654.76M | $582.86M | $618.06M | $599.22M | $626.66M | $558.89M | $592.25M | $575.43M | $595.42M | $523.21M | $564.03M | $522.55M | $560.67M | $503.18M | $531.04M | $413.08M | $511.98M | $612.00M | $490.39M | $326.55M | $213.60M | $556.37M | $574.05M | $573.88M | $601.83M | $467.61M |
| Low Forecast | $661.53M | $588.38M | $620.20M | $603.21M | $626.82M | $557.99M | $591.69M | $573.65M | $599.92M | $535.04M | $566.98M | $550.88M | $570.02M | $506.24M | $539.97M | $348.36M | $536.75M | $492.48M | $508.38M | $275.39M | $490.14M | $408.00M | $490.39M | $217.70M | $142.40M | $370.91M | $382.70M | $382.59M | $401.22M | $311.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.33% | 0.54% | 0.63% | 1.77% | 0.91% | 0.96% | - | 1.55% | 2.36% | 1.15% | 1.16% | 1.21% | 1.10% | 1.52% |
10 analysts predict ZBH's average Quarter EBITDA for Mar 24 to be $435.46M, with a high of $522.55M and a low of $348.36M. This is 137.05% upper than Zimmer Biomet's previous annual EBITDA (Dec 23) of $183.70M.
Zimmer Biomet Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 10 | 16 | 8 | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 10 | 18 | 21 | 10 | 10 | 13 | 9 | 9 | 17 | 11 | 10 | 20 | 10 | 14 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $162.80M | $209.90M | $232.50M | $-130.20M | $194.00M | - | $73.20M | $-83.90M | $145.60M | $141.90M | $198.10M | $333.70M | $242.50M |
| Avg Forecast | $600.67M | $478.58M | $528.38M | $505.04M | $547.71M | $433.18M | $475.45M | $451.00M | $511.38M | $403.91M | $442.40M | $425.38M | $473.08M | $366.42M | $410.94M | $19.50M | $444.50M | $329.79M | $375.24M | $15.42M | $377.22M | $154.67M | $338.38M | $12.19M | $-84.43M | $140.61M | $137.27M | $174.79M | $325.60M | $167.31M |
| High Forecast | $616.95M | $491.56M | $542.71M | $518.74M | $562.57M | $444.93M | $488.35M | $463.23M | $525.25M | $414.87M | $454.40M | $436.92M | $485.91M | $405.76M | $422.09M | $23.40M | $456.55M | $338.03M | $385.41M | $18.50M | $387.45M | $185.60M | $338.38M | $14.62M | $-67.54M | $168.73M | $164.73M | $209.75M | $390.72M | $200.77M |
| Low Forecast | $582.94M | $464.46M | $512.79M | $490.14M | $531.55M | $420.40M | $461.43M | $437.69M | $496.29M | $392.00M | $429.35M | $412.83M | $459.12M | $337.44M | $398.82M | $15.60M | $431.38M | $321.54M | $364.17M | $12.33M | $366.09M | $123.74M | $338.38M | $9.75M | $-101.31M | $112.49M | $109.82M | $139.84M | $260.48M | $133.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.49% | 0.56% | 15.08% | -0.35% | 1.25% | - | 6.01% | 0.99% | 1.04% | 1.03% | 1.13% | 1.02% | 1.45% |
Zimmer Biomet's average Quarter net income forecast for Dec 23 is $444.50M, with a range of $431.38M to $456.55M. ZBH's average Quarter net income forecast represents a 173.03% increase compared to the company's last Quarter net income of $162.80M (Sep 23).
Zimmer Biomet SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 10 | 16 | 8 | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 10 | 18 | 21 | 10 | 10 | 13 | 9 | 9 | 17 | 11 | 10 | 20 | 10 | 14 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $674.90M | $725.80M | $715.90M | $727.10M | $654.90M | - | $684.50M | $934.00M | $802.40M | $817.40M | $770.10M | $893.90M | $790.00M |
| Avg Forecast | $982.41M | $873.78M | $921.03M | $895.81M | $930.87M | $828.65M | $878.69M | $851.91M | $890.91M | $794.57M | $841.99M | $818.08M | $846.51M | $751.15M | $801.88M | $939.98M | $797.10M | $722.86M | $754.98M | $743.07M | $727.88M | $852.38M | $711.72M | $587.41M | $938.77M | $774.89M | $790.75M | $679.50M | $872.20M | $545.04M |
| High Forecast | $1.00B | $892.01M | $940.24M | $914.49M | $950.28M | $845.93M | $897.02M | $869.68M | $909.50M | $811.14M | $859.56M | $835.15M | $864.17M | $759.35M | $818.61M | $1.13B | $813.73M | $730.29M | $770.73M | $891.69M | $743.07M | $1.02B | $711.72M | $704.89M | $1.13B | $929.87M | $948.89M | $815.40M | $1.05B | $654.05M |
| Low Forecast | $960.11M | $853.95M | $900.12M | $875.47M | $909.74M | $809.84M | $858.74M | $832.57M | $870.69M | $776.53M | $822.88M | $799.52M | $827.30M | $734.73M | $783.68M | $751.99M | $779.01M | $714.76M | $737.84M | $594.46M | $711.36M | $681.90M | $711.72M | $469.93M | $751.01M | $619.91M | $632.60M | $543.60M | $697.76M | $436.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 0.96% | 0.96% | 1.00% | 0.77% | - | 1.17% | 0.99% | 1.04% | 1.03% | 1.13% | 1.02% | 1.45% |
Zimmer Biomet's average Quarter SG&A projection for Dec 23 is $797.10M, based on 18 Wall Street analysts, with a range of $779.01M to $813.73M. The forecast indicates a 18.11% rise compared to ZBH last annual SG&A of $674.90M (Sep 23).
Zimmer Biomet EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 10 | 16 | 8 | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 10 | 18 | 21 | 10 | 10 | 13 | 9 | 9 | 17 | 11 | 10 | 20 | 10 | 14 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.78 | $1.01 | $1.11 | $-0.62 | $0.92 | - | $0.35 | $-0.40 | $0.70 | $0.68 | $0.95 | $1.61 | $1.17 |
| Avg Forecast | $2.91 | $2.32 | $2.56 | $2.45 | $2.65 | $2.10 | $2.30 | $2.19 | $2.48 | $1.96 | $2.14 | $2.06 | $2.29 | $1.78 | $1.99 | $1.87 | $2.15 | $1.60 | $1.82 | $1.64 | $1.83 | $1.55 | $1.64 | $1.40 | $1.92 | $1.70 | $1.80 | $1.48 | $2.00 | $1.04 |
| High Forecast | $2.99 | $2.38 | $2.63 | $2.51 | $2.73 | $2.16 | $2.37 | $2.24 | $2.54 | $2.01 | $2.20 | $2.12 | $2.35 | $1.97 | $2.04 | $1.92 | $2.21 | $1.64 | $1.87 | $1.68 | $1.88 | $1.60 | $1.64 | $1.43 | $1.96 | $1.74 | $1.84 | $1.51 | $2.04 | $1.06 |
| Low Forecast | $2.82 | $2.25 | $2.48 | $2.37 | $2.58 | $2.04 | $2.24 | $2.12 | $2.40 | $1.90 | $2.08 | $2.00 | $2.22 | $1.63 | $1.93 | $1.82 | $2.09 | $1.56 | $1.76 | $1.59 | $1.77 | $1.51 | $1.64 | $1.38 | $1.89 | $1.68 | $1.78 | $1.46 | $1.97 | $1.02 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.49% | 0.56% | 0.68% | -0.34% | 0.59% | - | 0.25% | -0.21% | 0.41% | 0.38% | 0.64% | 0.80% | 1.13% |
According to 18 Wall Street analysts, Zimmer Biomet's projected average Quarter EPS for Dec 23 is $2.15, with a low estimate of $2.09 and a high estimate of $2.21. This represents a 176.10% increase compared to ZBH previous annual EPS of $0.78 (Sep 23).
Zimmer Biomet Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| BIO | Bio-Rad Laboratories | $326.22 | $565.00 | 73.20% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| EW | Edwards Lifesciences | $68.52 | $97.09 | 41.70% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| ZBH | Zimmer Biomet | $106.26 | $137.17 | 29.09% | Hold |
| MDT | Medtronic | $90.00 | $106.77 | 18.63% | Hold |
| ABT | Abbott Laboratories | $116.40 | $129.50 | 11.25% | Buy |
| BRKR | Bruker | $65.66 | $71.67 | 9.15% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
| SYK | Stryker | $370.25 | $305.00 | -17.62% | Buy |
| GKOS | Glaukos | $126.28 | $101.56 | -19.58% | Buy |
ZBH Forecast FAQ
Is Zimmer Biomet a good buy?
No, according to 19 Wall Street analysts, Zimmer Biomet (ZBH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 42.11% of ZBH's total ratings.
What is ZBH's price target?
Zimmer Biomet (ZBH) average price target is $137.17 with a range of $112 to $180, implying a 29.09% from its last price of $106.26. The data is based on 19 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Zimmer Biomet stock go up soon?
According to Wall Street analysts' prediction for ZBH stock, the company can go up by 29.09% (from the last price of $106.26 to the average price target of $137.17), up by 69.40% based on the highest stock price target, and up by 5.40% based on the lowest stock price target.
Can Zimmer Biomet stock reach $200?
ZBH's average twelve months analyst stock price target of $137.17 does not support the claim that Zimmer Biomet can reach $200 in the near future.
What is Zimmer Biomet's current price target trend?
2 Wall Street analysts forecast a $113.5 price target for Zimmer Biomet (ZBH) this month, up 6.81% from its last price of $106.26. Compared to the last 3 and 12 months, the average price target increased by 16.29% and increased by 22.68%, respectively.
What are Zimmer Biomet's analysts' financial forecasts?
Zimmer Biomet's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $8.44B (high $8.62B, low $8.25B), average EBITDA is $2.4B (high $2.45B, low $2.35B), average net income is $1.91B (high $1.96B, low $1.85B), average SG&A $3.49B (high $3.56B, low $3.41B), and average EPS is $9.24 (high $9.49, low $8.97). ZBH's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $8.89B (high $9.07B, low $8.68B), average EBITDA is $2.53B (high $2.58B, low $2.47B), average net income is $2.11B (high $2.17B, low $2.05B), average SG&A $3.67B (high $3.75B, low $3.59B), and average EPS is $10.24 (high $10.51, low $9.93).
Did the ZBH's actual financial results beat the analysts' financial forecasts?
Based on Zimmer Biomet's last annual report (Dec 2023), the company's revenue was $1.94B, which missed the average analysts forecast of $7.21B by -73.08%. Apple's EBITDA was $1.26B, missing the average prediction of $1.91B by -34.28%. The company's net income was $0, missing the average estimation of $1.16B by -100.00%. Apple's SG&A was $0, missing the average forecast of $3.02B by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $7.21 by -100.00%. In terms of the last quarterly report (Dec 2023), Zimmer Biomet's revenue was $183.7M, missing the average analysts' forecast of $1.93B by -90.47%. The company's EBITDA was $183.7M, missing the average prediction of $549.21M by -66.55%. Zimmer Biomet's net income was $0, missing the average estimation of $444.5M by -100.00%. The company's SG&A was $0, missing the average forecast of $797.1M by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $2.15 by -100.00%